nodes	percent_of_prediction	percent_of_DWPC	metapath
Sitaxentan—CYP2C19—urine—adrenal gland cancer	0.0463	0.143	CbGeAlD
Sitaxentan—EDNRB—Peptide GPCRs—GNRHR—adrenal gland cancer	0.0461	0.0681	CbGpPWpGaD
Sitaxentan—CYP2C9—urine—adrenal gland cancer	0.0359	0.111	CbGeAlD
Sitaxentan—EDNRB—adrenal cortex—adrenal gland cancer	0.0348	0.108	CbGeAlD
Sitaxentan—EDNRA—Peptide GPCRs—GNRHR—adrenal gland cancer	0.033	0.0488	CbGpPWpGaD
Sitaxentan—EDNRB—cardiac atrium—adrenal gland cancer	0.0288	0.0891	CbGeAlD
Sitaxentan—EDNRA—adrenal cortex—adrenal gland cancer	0.0288	0.0891	CbGeAlD
Sitaxentan—EDNRB—pituitary gland—adrenal gland cancer	0.0281	0.0871	CbGeAlD
Sitaxentan—EDNRA—GPCRs, Other—GNRHR—adrenal gland cancer	0.028	0.0413	CbGpPWpGaD
Sitaxentan—CYP3A4—urine—adrenal gland cancer	0.0274	0.0848	CbGeAlD
Sitaxentan—EDNRB—Endothelin Pathways—GNAS—adrenal gland cancer	0.0273	0.0404	CbGpPWpGaD
Sitaxentan—EDNRB—adrenal gland—adrenal gland cancer	0.0251	0.0778	CbGeAlD
Sitaxentan—EDNRB—Peptide GPCRs—TSHR—adrenal gland cancer	0.0246	0.0364	CbGpPWpGaD
Sitaxentan—EDNRA—cardiac atrium—adrenal gland cancer	0.0238	0.0737	CbGeAlD
Sitaxentan—EDNRA—pituitary gland—adrenal gland cancer	0.0232	0.072	CbGeAlD
Sitaxentan—EDNRB—G alpha (q) signalling events—GNRHR—adrenal gland cancer	0.022	0.0325	CbGpPWpGaD
Sitaxentan—EDNRA—EGFR-dependent Endothelin signaling events—EGFR—adrenal gland cancer	0.0211	0.0311	CbGpPWpGaD
Sitaxentan—EDNRA—adrenal gland—adrenal gland cancer	0.0208	0.0643	CbGeAlD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GNRHR—adrenal gland cancer	0.0196	0.029	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelin Pathways—GNAS—adrenal gland cancer	0.0196	0.0289	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide GPCRs—TSHR—adrenal gland cancer	0.0176	0.026	CbGpPWpGaD
Sitaxentan—EDNRB—Endothelins—CDC42—adrenal gland cancer	0.0171	0.0252	CbGpPWpGaD
Sitaxentan—EDNRB—Prostaglandin Synthesis and Regulation—PTGS2—adrenal gland cancer	0.0158	0.0234	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—GNRHR—adrenal gland cancer	0.0157	0.0232	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.0145	0.0215	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GNRHR—adrenal gland cancer	0.0141	0.0208	CbGpPWpGaD
Sitaxentan—EDNRB—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.0132	0.0194	CbGpPWpGaD
Sitaxentan—EDNRA—Endothelins—CDC42—adrenal gland cancer	0.0122	0.018	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.0118	0.0174	CbGpPWpGaD
Sitaxentan—EDNRA—Prostaglandin Synthesis and Regulation—PTGS2—adrenal gland cancer	0.0113	0.0167	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GNRHR—adrenal gland cancer	0.0111	0.0164	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—GNRHR—adrenal gland cancer	0.0104	0.0154	CbGpPWpGaD
Sitaxentan—EDNRA—G alpha (q) signalling events—GNRH1—adrenal gland cancer	0.00942	0.0139	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00872	0.0129	CbGpPWpGaD
Sitaxentan—CYP3A4—Codeine and Morphine Metabolism—ABCB1—adrenal gland cancer	0.00846	0.0125	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—GNRH1—adrenal gland cancer	0.00842	0.0124	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—GNRHR—adrenal gland cancer	0.00793	0.0117	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00777	0.0115	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00664	0.0098	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00626	0.00925	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—GNRH1—adrenal gland cancer	0.00624	0.00921	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—TSHR—adrenal gland cancer	0.00592	0.00874	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00569	0.0084	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—TSHR—adrenal gland cancer	0.00556	0.00821	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—GNRH1—adrenal gland cancer	0.00475	0.00702	CbGpPWpGaD
Sitaxentan—CYP2C19—Constitutive Androstane Receptor Pathway—ABCB1—adrenal gland cancer	0.00464	0.00686	CbGpPWpGaD
Sitaxentan—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—adrenal gland cancer	0.00463	0.00684	CbGpPWpGaD
Sitaxentan—EDNRB—Peptide ligand-binding receptors—POMC—adrenal gland cancer	0.00454	0.0067	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GNRHR—adrenal gland cancer	0.00448	0.00662	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—TSHR—adrenal gland cancer	0.00423	0.00625	CbGpPWpGaD
Sitaxentan—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—adrenal gland cancer	0.00423	0.00625	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GNRHR—adrenal gland cancer	0.00407	0.00601	CbGpPWpGaD
Sitaxentan—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—adrenal gland cancer	0.00403	0.00596	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00375	0.00554	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—GNAS—adrenal gland cancer	0.00344	0.00508	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00341	0.00503	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GNRHR—adrenal gland cancer	0.00336	0.00496	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00334	0.00494	CbGpPWpGaD
Sitaxentan—EDNRA—Peptide ligand-binding receptors—POMC—adrenal gland cancer	0.00325	0.0048	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00312	0.00461	CbGpPWpGaD
Sitaxentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00304	0.00449	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—TSHR—adrenal gland cancer	0.00304	0.00448	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—ZNRF3—adrenal gland cancer	0.00294	0.00434	CbGpPWpGaD
Sitaxentan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—adrenal gland cancer	0.00279	0.00412	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GNRH1—adrenal gland cancer	0.00268	0.00397	CbGpPWpGaD
Sitaxentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—adrenal gland cancer	0.00266	0.00393	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—GNAS—adrenal gland cancer	0.00246	0.00364	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GNRH1—adrenal gland cancer	0.00244	0.0036	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GNRHR—adrenal gland cancer	0.0024	0.00355	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—TSHR—adrenal gland cancer	0.00239	0.00353	CbGpPWpGaD
Sitaxentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.00232	0.00343	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR ligand binding—POMC—adrenal gland cancer	0.00232	0.00342	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SH3KBP1—adrenal gland cancer	0.00223	0.0033	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00218	0.00322	CbGpPWpGaD
Sitaxentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—POMC—adrenal gland cancer	0.00218	0.00322	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—TSHR—adrenal gland cancer	0.00217	0.00321	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—ZNRF3—adrenal gland cancer	0.0021	0.0031	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00204	0.00301	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GNRH1—adrenal gland cancer	0.00201	0.00297	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00194	0.00287	CbGpPWpGaD
Sitaxentan—CYP2C19—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00193	0.00285	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—CDC42—adrenal gland cancer	0.00185	0.00273	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—SPRY2—adrenal gland cancer	0.00184	0.00272	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TSHR—adrenal gland cancer	0.00179	0.00265	CbGpPWpGaD
Sitaxentan—CYP2C19—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	0.00178	0.00263	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—GNAS—adrenal gland cancer	0.00177	0.00261	CbGpPWpGaD
Sitaxentan—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00176	0.00259	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—MEN1—adrenal gland cancer	0.00169	0.00249	CbGpPWpGaD
Sitaxentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—adrenal gland cancer	0.00166	0.00246	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR ligand binding—POMC—adrenal gland cancer	0.00166	0.00245	CbGpPWpGaD
Sitaxentan—CYP2C9—Arachidonic acid metabolism—PTGS2—adrenal gland cancer	0.00162	0.00239	CbGpPWpGaD
Sitaxentan—CYP2C19—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.00156	0.00231	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—PRKACA—adrenal gland cancer	0.00156	0.0023	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—CDC42—adrenal gland cancer	0.00146	0.00215	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GNRH1—adrenal gland cancer	0.00144	0.00213	CbGpPWpGaD
Sitaxentan—CYP2C9—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.00142	0.0021	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—GNAS—adrenal gland cancer	0.00139	0.00206	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—CDC42—adrenal gland cancer	0.00132	0.00195	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—SPRY2—adrenal gland cancer	0.00132	0.00195	CbGpPWpGaD
Sitaxentan—EDNRB—GPCR downstream signaling—POMC—adrenal gland cancer	0.00131	0.00193	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—PRKACA—adrenal gland cancer	0.00129	0.0019	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TSHR—adrenal gland cancer	0.00128	0.0019	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—GNAS—adrenal gland cancer	0.00126	0.00187	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—MEN1—adrenal gland cancer	0.00121	0.00178	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—POMC—adrenal gland cancer	0.00119	0.00176	CbGpPWpGaD
Sitaxentan—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—adrenal gland cancer	0.00116	0.00171	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CDC42—adrenal gland cancer	0.00109	0.00161	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF2—adrenal gland cancer	0.00105	0.00155	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—GNAS—adrenal gland cancer	0.00104	0.00154	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—IGF1R—adrenal gland cancer	0.00102	0.0015	CbGpPWpGaD
Sitaxentan—CYP3A4—Phase 1 - Functionalization of compounds—POMC—adrenal gland cancer	0.000939	0.00139	CbGpPWpGaD
Sitaxentan—EDNRA—GPCR downstream signaling—POMC—adrenal gland cancer	0.000937	0.00138	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—PRKACA—adrenal gland cancer	0.000921	0.00136	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TERT—adrenal gland cancer	0.000876	0.00129	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—POMC—adrenal gland cancer	0.000851	0.00126	CbGpPWpGaD
Sitaxentan—CYP2C19—Biological oxidations—POMC—adrenal gland cancer	0.000829	0.00123	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.0008	0.00118	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CDC42—adrenal gland cancer	0.000781	0.00115	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BAD—adrenal gland cancer	0.000762	0.00113	CbGpPWpGaD
Sitaxentan—CYP2C9—Biological oxidations—POMC—adrenal gland cancer	0.000756	0.00112	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF2—adrenal gland cancer	0.000753	0.00111	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—GNAS—adrenal gland cancer	0.000747	0.0011	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SDHB—adrenal gland cancer	0.000742	0.0011	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—MED12—adrenal gland cancer	0.00073	0.00108	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—IGF1R—adrenal gland cancer	0.000728	0.00108	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—POMC—adrenal gland cancer	0.000702	0.00104	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—BRAF—adrenal gland cancer	0.000694	0.00102	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SDHB—adrenal gland cancer	0.000676	0.000999	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling by GPCR—EGFR—adrenal gland cancer	0.000672	0.000993	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TERT—adrenal gland cancer	0.000627	0.000926	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000584	0.000862	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BAD—adrenal gland cancer	0.000545	0.000806	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PRKACA—adrenal gland cancer	0.000532	0.000786	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—POMC—adrenal gland cancer	0.000503	0.000743	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000501	0.00074	CbGpPWpGaD
Sitaxentan—CYP3A4—Biological oxidations—POMC—adrenal gland cancer	0.000499	0.000737	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—BRAF—adrenal gland cancer	0.000496	0.000733	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling by GPCR—EGFR—adrenal gland cancer	0.000481	0.000711	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—RRM1—adrenal gland cancer	0.000478	0.000706	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—SDHD—adrenal gland cancer	0.000478	0.000706	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SDHB—adrenal gland cancer	0.000446	0.000659	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—RRM1—adrenal gland cancer	0.000436	0.000644	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—SDHD—adrenal gland cancer	0.000436	0.000644	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—EGFR—adrenal gland cancer	0.000397	0.000587	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—CTNNB1—adrenal gland cancer	0.000359	0.00053	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—MED12—adrenal gland cancer	0.000356	0.000526	CbGpPWpGaD
Sitaxentan—EDNRB—Signaling Pathways—TP53—adrenal gland cancer	0.000333	0.000493	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—MED12—adrenal gland cancer	0.000325	0.00048	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	0.000319	0.000471	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—POMC—adrenal gland cancer	0.00029	0.000429	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—RRM1—adrenal gland cancer	0.000287	0.000425	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—SDHD—adrenal gland cancer	0.000287	0.000425	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—EGFR—adrenal gland cancer	0.000284	0.00042	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PRKACA—adrenal gland cancer	0.00026	0.000384	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	0.000254	0.000375	CbGpPWpGaD
Sitaxentan—EDNRA—Signaling Pathways—TP53—adrenal gland cancer	0.000239	0.000353	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PRKACA—adrenal gland cancer	0.000237	0.00035	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—adrenal gland cancer	0.000232	0.000342	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—MED12—adrenal gland cancer	0.000214	0.000317	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—GNAS—adrenal gland cancer	0.000211	0.000311	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—ABCB1—adrenal gland cancer	0.000207	0.000305	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—GNAS—adrenal gland cancer	0.000192	0.000284	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—ABCB1—adrenal gland cancer	0.000188	0.000278	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PRKACA—adrenal gland cancer	0.000156	0.000231	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—POMC—adrenal gland cancer	0.000142	0.00021	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—POMC—adrenal gland cancer	0.000129	0.000191	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—GNAS—adrenal gland cancer	0.000127	0.000187	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—ABCB1—adrenal gland cancer	0.000124	0.000184	CbGpPWpGaD
Sitaxentan—CYP2C19—Metabolism—PTGS2—adrenal gland cancer	0.000113	0.000167	CbGpPWpGaD
Sitaxentan—CYP2C9—Metabolism—PTGS2—adrenal gland cancer	0.000103	0.000152	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—POMC—adrenal gland cancer	8.53e-05	0.000126	CbGpPWpGaD
Sitaxentan—CYP3A4—Metabolism—PTGS2—adrenal gland cancer	6.8e-05	0.000101	CbGpPWpGaD
